These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9484869)

  • 21. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S; Swarz H; Breisch SA; Maroli AN
    Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
    Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K
    Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Grepafloxacin (Raxar)].
    Friis HM
    Ugeskr Laeger; 1998 Jul; 160(30):4438-41. PubMed ID: 9691842
    [No Abstract]   [Full Text] [Related]  

  • 26. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 27. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 29. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative grepafloxacin phototoxicity in mouse skin.
    Owen K
    J Antimicrob Chemother; 1998 Aug; 42(2):261-4. PubMed ID: 9738848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
    Yoshizumi S; Takahashi Y; Murata M; Domon H; Furuya N; Ishii Y; Matsumoto T; Ohno A; Tateda K; Miyazaki S; Yamaguchi K
    J Antimicrob Chemother; 2001 Jul; 48(1):137-40. PubMed ID: 11418525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.
    Paton JH; Reeves DS
    Drugs; 1988 Aug; 36(2):193-228. PubMed ID: 3053126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens.
    Zerva L; Marshall SA; Jones RN
    J Antimicrob Chemother; 1996 Oct; 38(4):742-4. PubMed ID: 8937972
    [No Abstract]   [Full Text] [Related]  

  • 34. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
    Ernst ME; Ernst EJ; Klepser ME
    Am J Health Syst Pharm; 1997 Nov; 54(22):2569-84. PubMed ID: 9397218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinolones: clinical use and formulary considerations.
    Cunha BA
    Adv Ther; 1998; 15(5):277-87. PubMed ID: 10345149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
    Shakibaei M; Baumann-Wilschke I; Rücker M; Stahlmann R
    Arch Toxicol; 2002 Jan; 75(11-12):725-33. PubMed ID: 11876506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.